dopamine precursor

Class

levodopa/carbidopa (extended-release)

Levodopa is the metabolic precursor of dopamine, the neurotransmitter whose progressive loss from neurons connecting the substantia nigra to the striatum underlies the movement problems seen in Parkinson's disease. Dopamine itself cannot cross the blood-brain barrier, so patients are instead given levodopa, which is actively transported into the brain and converted there into dopamine. Carbidopa, an enzyme inhibitor that does not cross into the brain, is combined with levodopa to block its premature conversion in peripheral tissues, increasing the fraction that reaches the brain and reducing peripheral side effects such as nausea. This levodopa/carbidopa combination remains the foundational symptomatic treatment for Parkinson's disease and related parkinsonian disorders. With years of use, the short duration of action of standard oral levodopa produces fluctuating brain dopamine levels between doses, causing periods of symptom return ('wearing-off') and involuntary movements called dyskinesias. Extended-release oral formulations, continuous intestinal or subcutaneous infusions, and inhaled rescue formulations all aim to smooth out these fluctuations, delivering steadier drug exposure than conventional tablets. Rather than introducing a new pharmacological target, this generation of therapies re-engineers delivery of the same precursor molecule to preserve its benefit while limiting motor complications caused by uneven dosing.